Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine
Authors:
- Dennis M KlinmanDKDennis M Klinman
- Masaki YamamotoMYMasaki Yamamoto
- Debra TrossDTDebra Tross
- Koji TomaruKTKoji Tomaru
- 22 September 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 9 (12) , 1477-1486
Abstract
The intentional release of anthrax spores in 2001 confirmed this pathogen's ability to cause widespread panic, morbidity and mortality. While individuals exposed to anthrax can be successfully treated with antibiotics, pre-exposure vaccination can reduce susceptibility to infection-induced illness. Concern over the safety and immunogenicity of the licensed US vaccine (Anthrax Vaccine Adsorbed (AVA)) has fueled research into alternatives. Second-generation anthrax vaccines based on purified recombinant protective antigen (rPA) have entered clinical trials. These rPA vaccines induce neutralizing antibodies that prevent illness, but the magnitude and duration of the resultant protective response is modest. Efforts are underway to bolster the immunogenicity of rPA by combining it with adjuvants and other immunostimulatory agents. Third generation vaccines are under development that utilize a wide variety of immunization platforms, antigens, adjuvants, delivery methods and routes of delivery to optimize the in...Keywords
This publication has 112 references indexed in Scilit:
- Efficacy of a Vaccine Based on Protective Antigen and Killed Spores against Experimental Inhalational AnthraxInfection and Immunity, 2009
- Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic BackgroundClinical and Vaccine Immunology, 2008
- Recombinant Exosporium Protein BclA of Bacillus anthracis Is Effective as a Booster for Mice Primed with Suboptimal Amounts of Protective AntigenInfection and Immunity, 2007
- Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvantJournal of Immune Based Therapies and Vaccines, 2007
- Noncapsulated Toxinogenic Bacillus anthracis Presents a Specific Growth and Dissemination Pattern in Naive and Protective Antigen-Immune MiceInfection and Immunity, 2007
- Systemic but not mucosal immunity induced by AVA prevents inhalational anthraxMicrobes and Infection, 2007
- Prophylaxis and Therapy of Inhalational Anthrax by a Novel Monoclonal Antibody to Protective Antigen That Mimics Vaccine-Induced ImmunityInfection and Immunity, 2006
- Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthraxProceedings of the National Academy of Sciences, 2006
- Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in miceBiologicals, 2004
- The Three Factors of Anthrax Toxin: their Immunogenicity and Lack of Demonstrable Enzymic ActivityJournal of General Microbiology, 1963